365 related articles for article (PubMed ID: 14619976)
1. Antiproliferative role of vitamin D and its analogs--a brief overview.
Banerjee P; Chatterjee M
Mol Cell Biochem; 2003 Nov; 253(1-2):247-54. PubMed ID: 14619976
[TBL] [Abstract][Full Text] [Related]
2. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
3. Structure and the Anticancer Activity of Vitamin D Receptor Agonists.
Powała A; Żołek T; Brown G; Kutner A
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928329
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; van den Bemd GJ; Dorssers LC; Birkenhäger JC; van Leeuwen JP
Cancer Res; 1994 Nov; 54(21):5711-7. PubMed ID: 7923220
[TBL] [Abstract][Full Text] [Related]
5. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review.
Bortman P; Folgueira MA; Katayama ML; Snitcovsky IM; Brentani MM
Braz J Med Biol Res; 2002 Jan; 35(1):1-9. PubMed ID: 11743608
[TBL] [Abstract][Full Text] [Related]
6. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
Campbell MJ; Reddy GS; Koeffler HP
J Cell Biochem; 1997 Sep; 66(3):413-25. PubMed ID: 9257197
[TBL] [Abstract][Full Text] [Related]
7. Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.
Boehm MF; Fitzgerald P; Zou A; Elgort MG; Bischoff ED; Mere L; Mais DE; Bissonnette RP; Heyman RA; Nadzan AM; Reichman M; Allegretto EA
Chem Biol; 1999 May; 6(5):265-75. PubMed ID: 10322128
[TBL] [Abstract][Full Text] [Related]
8. The antiproliferative effect of vitamin D analogs on MCF-7 human breast cancer cells.
Brenner RV; Shabahang M; Schumaker LM; Nauta RJ; Uskokovic MR; Evans SR; Buras RR
Cancer Lett; 1995 May; 92(1):77-82. PubMed ID: 7757962
[TBL] [Abstract][Full Text] [Related]
9. The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression.
Shany S; Levy Y; Lahav-Cohen M
Steroids; 2001; 66(3-5):319-25. PubMed ID: 11179740
[TBL] [Abstract][Full Text] [Related]
10. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
11. 1,25-Dihydroxyvitamin D
Li M; Li L; Zhang L; Hu W; Shen J; Xiao Z; Wu X; Chan FL; Cho CH
Life Sci; 2017 Jun; 179():88-97. PubMed ID: 28465245
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
13. Differential antitumor effects of vitamin D analogues on colorectal carcinoma in culture.
Wierzbicka JM; Binek A; Ahrends T; Nowacka JD; Szydłowska A; Turczyk Ł; Wąsiewicz T; Wierzbicki PM; Sądej R; Tuckey RC; Slominski AT; Chybicki J; Adrych K; Kmieć Z; Żmijewski MA
Int J Oncol; 2015 Sep; 47(3):1084-96. PubMed ID: 26260259
[TBL] [Abstract][Full Text] [Related]
14. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
15. Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system.
Zhao XY; Eccleshall TR; Krishnan AV; Gross C; Feldman D
Mol Endocrinol; 1997 Mar; 11(3):366-78. PubMed ID: 9058382
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines.
Zhuang SH; Schwartz GG; Cameron D; Burnstein KL
Mol Cell Endocrinol; 1997 Jan; 126(1):83-90. PubMed ID: 9027366
[TBL] [Abstract][Full Text] [Related]
17. Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors.
Wasiewicz T; Piotrowska A; Wierzbicka J; Slominski AT; Zmijewski MA
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30200275
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition of human colon adenocarcinoma-derived Caco-2 cells by 1,25-dihydroxyvitamin D3 and two synthetic analogs: relation to in vitro hypercalcemic potential.
Cross HS; Farsoudi KH; Peterlik M
Naunyn Schmiedebergs Arch Pharmacol; 1993 Jan; 347(1):105-10. PubMed ID: 8446178
[TBL] [Abstract][Full Text] [Related]
19. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs.
Schwartz GG; Oeler TA; Uskoković MR; Bahnson RR
Anticancer Res; 1994; 14(3A):1077-81. PubMed ID: 8074453
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D analogs: new therapeutic agents for the treatment of squamous cancer and its associated hypercalcemia.
Yu J; Papavasiliou V; Rhim J; Goltzman D; Kremer R
Anticancer Drugs; 1995 Feb; 6(1):101-8. PubMed ID: 7756673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]